<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Paraffin-embedded diagnostic biopsy materials from a large cohort of pediatric and adolescent patients with mature B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) treated on the Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Group arm of an international cooperative trial were studied to determine their phenotypic features and the feasibility of using targeted bioimmune therapies </plain></SENT>
<SENT sid="1" pm="."><plain>There were 345 patients eligible for analysis: 208 with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), 43 with high-grade B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Burkitt-like (HGBL), and 94 with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Samples were immunophenotyped centrally using a standard panel that included CD20, CD79a, CD3, and CD45RO </plain></SENT>
<SENT sid="3" pm="."><plain>Additional staining with CD22 was performed on a subset of cases </plain></SENT>
<SENT sid="4" pm="."><plain>Immunophenotypic studies showed positive staining with CD20 in 100% of cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and HGBL and in 98% of cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>CD22 expression was present in <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and in 87% of cases HGBL </plain></SENT>
<SENT sid="6" pm="."><plain>This study indicates that immune-based therapies such as rituximab and ibritumomab-tiuxetan (anti-CD20) and epratuzumab (anti-CD22) are feasible in pediatric cases of mature B-cell NHLs </plain></SENT>
</text></document>